Company / Working Capital
Acadia Pharmaceuticals Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$785.0M
FY2025
5-year range
$361.9M / $785.0M
FY2021-FY2025
Trend
+44.4%
vs FY2024
Sector context
#52 of 213
Health Care
What the data says
Acadia Pharmaceuticals's working capital of $785M is higher than 76% of companies in the Health Care sector (FY2025). Working Capital has fluctuated over the past 10 years, ranging from $324M in FY2017 to $785M in FY2025.
Based on SEC 10-K filings.
$785M in FY2025 with a 5-year CAGR of +5.1%. Top quartile in the Health Care sector.
Improved from $362M to $785M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +27.1%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
-16.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2025, working capital increased 44.4% year-over-year.
- Ranks #52 out of 213 companies in the Health Care sector.
- Lowest working capital in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $785.0M | +44.4% |
| FY2024 | $543.4M | +50.2% |
| FY2023 | $361.9M | -5.3% |
| FY2022 | $382.3M | -26.7% |
| FY2021 | $521.8M | -14.7% |
| FY2020 | $611.6M | -10.8% |
| FY2019 | $685.4M | +46.9% |
| FY2018 | $466.5M | +43.8% |
| FY2017 | $324.4M | -35.8% |
| FY2016 | $505.3M | +156.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026